ORPHA:2612
Linear nevus sebaceus syndrome
Also known as: Nevus sebaceus of Jadassohn · Nevus sebaceus syndrome · Organoid nevus syndrome · Schimmelpenning syndrome · Solomon syndrome
Clinical definition (Orphanet)
A rare nevus syndrome characterized by the association of an nevus sebaceous with a broad spectrum of abnormalities that affect many organ systems, most commonly the eye, skeletal and central nervous system.
How rare: How common this is has not been clearly measured.
Is anyone studying this?
931
931 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
931 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
389 in the last 10 years · high confidence · 89.3th percentile (publications denominator)
Is a treatment being tested?
369
trials for this specific condition
369 interventional trials matched this specific condition name; 145 currently recruiting in our sample.
Data as of 26 July 2026
369 interventional trials — more than 59.2% of diseases in the trials denominator have none at all (151 of 255; this disease is at the 99th percentile).
high confidence · 99th percentile (trials denominator)
Do we know what causes it?
Yes — we know a specific gene responsible (KRAS).
GenCC classification: Strong.
Who's working on it?
874
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhang X4 papers · 2026
State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Papers in Europe PMC - 02Nischal KK3 papers · 2026
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Papers in Europe PMC - 03Singh P3 papers · 2024
Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Papers in Europe PMC - 04Verma P3 papers · 2024
Department of Dermatology and STD, Vardhaman Mahavir Medical College and Safdarjang hospital, New Delhi, India.
Papers in Europe PMC - 05Zhang J3 papers · 2022
Department of Dermatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 06Zhang Q3 papers · 2025
Department of Pediatric Hematology-Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 07Agrawal S2 papers · 2024
Oculoplasty and Orbital Tumor Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC - 08Bajaj MS2 papers · 2024
Oculoplasty and Orbital Tumor Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC - 09Bhankhodia V2 papers · 2025
Department of Pathology, AIIMS Rajkot, Gujarat - 360110, India.
Papers in Europe PMC - 10Cao Y2 papers · 2022
Department of Dermatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
369 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04146298·Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
- NCT05815173·Ladarixin With Sotorasib in Advanced NSCLC
- NCT07601048·A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- NCT07656376·Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
- NCT07455617·Study of ABO2102 in KRAS-Mutated Solid Tumors
- NCT07668752·A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
- NCT06625775·Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT06545201·RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
- NCT05398094·Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
- NCT07562581·A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
- NCT07463677·Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT06947811·A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
- NCT07639242·Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
- NCT07198841·IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
- NCT06128551·Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Observational and natural-history studies
29 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07557849·Multicentric Database for KRAS Mutant Pancreatic Cancer
- NCT07122882·Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
- NCT05630989·A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
- NCT07198620·A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China
- NCT06449989·Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
- NCT04151342·CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"Linear nevus sebaceus syndrome" OR "Nevus sebaceus of Jadassohn" OR "Nevus sebaceus syndrome" OR "Organoid nevus syndrome" OR "Schimmelpenning syndrome" OR "Solomon syndrome" OR "Nevus sebaceous of Jadassohn" OR "Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic" OR "linear sebaceous Nevus" OR "organoid Nevus"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Linear nevus sebaceus syndrome" OR "Nevus sebaceus of Jadassohn" OR "Nevus sebaceus of the Jadassohn" OR "Nevus sebaceus syndrome" OR "Organoid nevus syndrome" OR "Schimmelpenning syndrome" OR "Solomon syndrome" OR "Nevus sebaceous of Jadassohn" OR "Nevus sebaceous of the Jadassohn" OR "Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic" OR "linear sebaceous Nevus" OR "organoid Nevus" OR "KRAS"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 369 interventional · 29 observational · 6 expanded access. Only interventional studies enter the trial headline.
Cross-references (from Mondo): OMIM:163200 UMLS:C4552097 NCIT:C4678
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus